AZN Receives European Union Approval for Klygefa to Treat Adults With Generalised Myasthenia Gravis

· The NYC Memo

AstraZeneca PLC announced that Klygefa (gefurulimab) received marketing authorization in the European Union for the treatment of adults with generalised myasthenia gravis. The approval was based on results from the PREVAIL Phase III clinical trial, which demonstrated statistically significant improvement in the Myasthenia Gravis Activities of Daily Living score.

Developed by Alexion, AstraZeneca Rare Disease, Klygefa is a dual-binding nanobody C5 inhibitor administered once weekly via subcutaneous autoinjector.

Related memos

More from the NYC Memo newswire